OptimizeRx price target lowered to $18 from $25 at Lake Street

Lake Street analyst Eric Martinuzzi lowered the firm’s price target on OptimizeRx to $18 from $25 and keeps a Buy rating on the shares. OptimizeRx posted a "good Q4," but gave a "disappointing" outlook as the company guided revenue below expectations for both Q1 and the full year, the analyst tells investors. Optimize enters the year with 40%-60% of its revenue already in backlog, noted the firm, which added that "if we have learned anything from 2022, it is how quickly the market can pivot and thwart new business development."